60 Degrees Pharmaceuticals, Inc. SXTP
60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is an infectious disease drug developer. Its lead program, Arakoda (tafenoquine), is in Phase 2 for Malaria prophylaxis/prevention. Its next catalyst on record is tafenoquine: Company will request a pre-sNDA meeting with FDA in January 2027 to discuss data requirements, patient population, regulatory pathway, and post-marketing requirements for tafenoquine in babesiosis. (January 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: tafenoquine — Company will request a pre-sNDA meeting with FDA in January 2027 to discuss data requirements, patient population, regulatory pathway, and post-marketing requirements for tafenoquine in babesiosis. (January 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Arakoda (tafenoquine) | Malaria preventative treatment | small molecule | Approved |
| Tafenoquine | Babesiosis | small molecule | Phase 2 |
Recent results and decisions
- Oct 23, 2026mixed Interim chronic babesiosis study screening has not produced species-specific B. microti signal in 2 of 9 subjects screened.
2/9 Genus-level molecular screening signal Early chronic-study screening has not produced a species-specific B. microti signal.
Filing - Oct 23, 2026positive Three expanded-access patients with relapsing babesiosis were NAT-negative after tafenoquine treatment; cases 4-5 approaching disclosure.
The first three patients were NAT- negative after treatment; cases 4– 5 are approaching disclosure.
Filing - Oct 23, 2026n/a Hospital study randomized 30 subjects with severe babesiosis; blinded follow-up completes in early January 2027.
Blinded follow-up completes in early January 2027; unblinding follows.
Filing
5 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.